Andrew J. Dannenberg

BioVentures (United States) — United States

Medicine · Health Sciences

102h-index33.8kcitations656works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(169), Estrogen and related hormone effects(131), Cancer Risks and Factors(66), Cancer, Lipids, and Metabolism(63), Adipokines, Inflammation, and Metabolic Diseases(61)

Publications656 total

Nutritional and Immune State of Gastric Cancer Patients Deteriorate During the Preoperative Period.
PubMed·2026
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth
Frontiers in Oncology·2026Open Access
Evexomostat (SDX-7320), a Methionine Aminopeptidase Type 2 (METAP2) Inhibitor, Stimulates Weight Loss and Inhibits Obesity-Accelerated Tumor Growth
2026Open Access
Abstract C031: Evexomostat (SDX-7320), a methionine aminopeptidase type 2 (METAP2) inhibitor, inhibits obesity-accelerated tumor growth and stimulates weight loss in obese mice
Clinical Cancer Research·2025
Data from Association of a Healthy Lifestyle Index with Risk of Breast Cancer among Women with Normal Body Mass Index in the UK Biobank
2025Open Access
Supplementary table from Association of a Healthy Lifestyle Index with Risk of Breast Cancer among Women with Normal Body Mass Index in the UK Biobank
2025Open Access
Dietary Polyunsaturated Fatty Acids Regulate Dendritic Cell Function via Nrf2-dependent Control of Ferroptosis
2025Open Access
ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage
Angiogenesis·2025· 4 citedOpen Access
Table S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S1 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S2 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Supplementary Data from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Table S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S5 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Data from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Table S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
Figure S4 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity
2024Open Access
page 1 of 33Next →

Frequent Co-authors

Kotha Subbaramaiah(26), Clifford A. Hudis(8), Jaime L. Masferrer(6), Baoheng Du(6), Nasser K. Altorki(5), Louise R. Howe(5), Neil M. Iyengar(4), Robert A. Soslow(4), Alane Koki(4), Xi Kathy Zhou(4), Priya Bhardwaj(4), B. Mark Woerner(3), Jay O. Boyle(3), Fan Zhang(3), Patrick G. Morris(3), Levy Kopelovich(3), Scott M. Lippman(3), Juan Mestre(3), Wen Jing Chung(2), Pedro Michaluart(2)